Measurement of Natriuretic Hormone Peptides in Exacerbation of Asthma
NCT ID: NCT01690793
Last Updated: 2015-05-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2009-02-28
2011-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictive Factors for Exacerbation Outcome in Severe Refractory Asthmatics
NCT00721097
Daily Monitoring of Exhaled Nitric Oxide in Asthmatic Patients
NCT01113853
NHLBI/NICHD Collaborative Studies of Asthma in Pregnancy
NCT00000578
Exhaled Breath Condensate as a Measure of Airway Inflammation in Children With Asthma
NCT00078208
Asthma: Phenotyping Exacerbations 3
NCT05446090
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Measurement of Natriuretic Hormone Peptides in individuals suffering from exacerbation of asthma.
2. Measurement of Natriuretic Hormone Peptides 5-7 days after initiation of treatment of exacerbation of asthma.
3. Measurement of Natriuretic Hormone Peptides 10-14 days after initiation of treatment of exacerbation of asthma.
3 comparisons of Natriuretic Hormone Peptides levels will be made:
1. Exacerbation compared to 5-7 days after initiation of treatment
2. Exacerbation compared to 10-14 days after initiation of treatment
3. 5-7 days after initiation of treatment compared to 10-14 days after initiation of treatment.
Samples of blood will be secured in the Division of Allergy/Immunology at the University of South Florida, Joy McCann Culverhouse Airways Disease Center. All samples will be appropriately coded to maintain confidentiality. Blood specimens will be held at minus 20 degrees Celsius.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Females who are pregnant or lactating are not eligible.
* Read and comprehend English.
* Ability to give informed consent.
* Seen in the outpatient setting at one of the clinic.
* The subject must have a history of physician diagnosed asthma for at least 1 year and must have an exacerbation of asthma for entry into the study.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of South Florida
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Richard Lockey
prinicpal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Usf Asthma Allergy and Immunology Cru
Tampa, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
acute asthma
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.